Topics:
Lung Cancer • Radiation Oncology • Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer
Do you consider additional chemotherapy or durvalumab after definitive concurrent chemo/RT for Stage II NSCLC for patients who are not surgical candidates?
Would PDL-1 status impact your decision?
Answer from: Radiation Oncologist at Community Practice
Staging is man-made and somewhat capricious and as stands now essentially completely unmoored from biology in NSCLC. Durvalumab is obviously very moored to biology in NSCLC. There are times we "extrapolate" in oncology; it's tough not to do this in settings where no *specific* data exists but "adjac...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Intriguing given the results from the PACIFIC trial presented and published in 2017 (PFS benefit) and updated very recently (OS benefit). However, in the absence of definitive data in which the benefit clearly outweighs the potential harm, I would not recommend adjuvant durvalumab to patients treate...
Answer from: Medical Oncologist at Academic Institution
If a patient is not a candidate for surgery but has no contra indication to treatment with durvalumab, I would offer it.